louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01347177: Clinical Trial of Zirconia and Metal Adhesive Bridges
Official title: A Single-centre Randomised Controlled Clinical Trial of Zirconia-based Versus Metal-based Adhesive Bridges for Replacing 2 Missing Teeth or Less in Adults.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Missing Teeth
Lead sponsor: Queen Mary University of London
Sponsor class: OTHER
First posted: 2011-05-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Adhesive bridges are becoming popular in patients with congenitally missing teeth and these are type of bridges that can be done with only minimal or with no preparation to replace the missing tooth/teeth. The best clinical gain is the minimal tooth preparation or no need for the removal of tooth substance. Treatment for this type of bridges does not usually require anaesthesia. In addition, adhesive bridges can provide reasonable aesthetical outcome with minimal cost and reduced chair time.

The biggest issue is that high failure rate in the long term, and gray colour shining through the metal wing cemented onto the abutment tooth. This can compromise the aesthetical outcome. The aesthetical problem can be solved by the use of zirconia all ceramic material to construct the bridge.


Eligibility criteria: Inclusion Criteria:

* Male or female ≥ 18 years of age
* Has a maximum of 2 units requiring placement
* Is a regular dental attendee and agree to return for assessments
* Written subject informed consent (IC) for this protocol will be obtained prior to study enrolment. Each subject will be required to sign and date the IC form prior to their participation
* Sound or minimally restored abutment(s)

Exclusion Criteria:

* The presence of any periodontal pocket depths equal or above 4 mm with active periodontal disease
* Any history of adverse reaction to clinical materials to be used in this study
* They are pregnant or had serious medical condition that may interfere with the dental treatment
* Acquired tooth loss more than 2 units requiring replacement
* Participants who have parafunctional habits
* Severe Class II Div II cases

Primary outcomes:
measure: Clinical survival of adhesive bridges
timeFrame: 5 Years
Secondary outcomes:
measure: Quality of life, aesthetic outcome.
timeFrame: 18 months
measure: Marginal discrepancy evaluation.
timeFrame: After cementation
measure: Economic evaluation
timeFrame: 5 years
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Barts and The London, School of Medicine and Dentistry
Study officials:
affiliation: Queen Mary University of London
name: Aylin Baysan, BDS, MSc, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Queen Mary University of London
name: Amani Agha, BDS,MSc
role: STUDY_DIRECTOR
References:
Clinical trial NCT04786977: Physiologic Measure of VIPN
Official title: Development of a Physiologic Measure of Vincristine Induced Peripheral Neuropathy in Children and Adolescents
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chemotherapy-induced Peripheral Neuropathy
Lead sponsor: Children's National Research Institute
Sponsor class: OTHER
First posted: 2021-03-08
Enrollment: 40
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 30 patients and 10 healthy volunteers will be enrolled for this study.

Brief summary: The purpose of this study is the development of a physiologic endpoint using a novel technology that would provide an objective, easy to use and more sensitive assessment of VIPN in children and adolescents. The ability to more easily detect and monitor VIPN, even before it is clinically evident, would facilitate optimizing the dosing of vincristine for maximal disease response while minimizing the risk of lifelong functional deficits affecting quality of life. This approach would also enable the development of specific therapies to minimize or eliminate the occurrence of VIPN in children and adolescents. This is a single site study that aims to develop a novel device to evaluate and characterize vincristine-induced neuropathic pain. The investigators will enroll patients with ALL following the Delayed Intensification (DI) phase of treatment. At each study visit, the investigators will evaluate the nPRD as well as the TNS-PV. The nPRD will inform the neuropathy index which will be used to compare to the TNS-PV. We anticipate a correlation between the two.


Eligibility criteria: Inclusion Criteria:

* 6-18 years of age at the start of the study, are receiving vincristine in DI (clinical study population) and are willing and able to provide informed consent or assent to study participation.

Exclusion Criteria:

* have eye pathology which precludes pupillometry, are hemodynamically unstable, or are pregnant.

Primary outcomes:
measure: Characterization of neuropathy index in patients with VIPN
timeFrame: 1 Year
Secondary outcomes:
measure: Correlation of neuropathy index with the TNS-PV
timeFrame: 1 Year
Other outcomes:
Locations:
city: Washington
country: United States
facility: Children's National Health System
state: District of Columbia
Study officials:
References:
Clinical trial NCT01328977: Trial to Assess Best Methods for Engaging Academic Physicians in Grateful Patient Philanthropy
Official title: Trial to Assess Best Methods for Engaging Academic Physicians in Grateful Patient Philanthropy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physician's Role
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2011-04-05
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study attempted to identify the best method for educating and engaging academic physicians in grateful patient philanthropy.

Detailed description: In this small trial assessing the impact of educational methodologies, we are looking to determine which of the following 3 approaches will be most successful in engaging academic physicians in grateful patient philanthropy;

* email advice
* didactic session led by experts
* one-on-one coaching by development professionals

Eligibility criteria: Inclusion Criteria:

* academic physicians

Exclusion Criteria:

* having secured grateful patient philanthropy in past

Primary outcomes:
measure: qualified referrals to development office
timeFrame: 6 month follow-up period
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: JHU SOM
name: Scott M Wright, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01210677: Cardiac Sarcoidosis Response To Steroids Trial
Official title: CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Cardiac Sarcoidosis
Sarcoidosis
Keywords: Cardiac Sarcoidosis
Sarcoidosis
Lead sponsor: Ottawa Heart Institute Research Corporation
Sponsor class: OTHER
First posted: 2010-09-28
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There are no published clinical consensus guidelines on the treatment of cardiac sarcoidosis. Corticosteroid therapy is advocated by some experts, but is based on small observational studies, with varied clinical response.

Objectives of this trial:

* to systemically assess the response of patients with cardiac sarcoidosis, to treatment with corticosteroids
* to identify the clinical predictors of response to treatment with corticosteroids
* to assess the utility of imaging with PET and MRI to predict response to treatment with corticosteroids
* to determine the prevalence of cardiac sarcoidosis in young patients with unexplained heart block and in patients with unexplained dilated cardiomyopathy associated with ventricular tachycardia
* to use the data from this pilot study to assess the need, feasibility, and sample size for a larger multicentre trial


Eligibility criteria: Inclusion Criteria:

* evidence of clinical cardiac sarcoidosis causing significant conduction system disease (defined as complete right bundle branch block and left axis deviation or left bundle branch block or second or third degree AV block in young patients (\< 60 yrs) AND/OR
* evidence of clinical cardiac sarcoidosis causing non-ischemic dilated cardiomyopathy and sustained ventricular tachycardia AND
* PET or MRI imaging supporting the diagnosis of cardiac sarcoidosis

Exclusion Criteria:

* unable or unwilling to provide informed consent
* history of noncompliance of medical therapy
* patients with active infection
* patients with active inflammatory disease not related to sarcoidosis
* patients with other known causes of heart block or LV dysfunction
* patients with known active malignancy
* patients wwho are pregnant or lactating
* patients with other indications for steroids

Primary outcomes:
measure: Heart failure hospitalization and sustained ventricular arrhythmia
timeFrame: 3 months
Secondary outcomes:
measure: Change in disease activity by PET imaging
timeFrame: 3 months
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: University of Ottawa Heart Institute
state: Ontario
Study officials:
affiliation: Ottawa Heart Institute Research Corporation
name: David Birnie, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ottawa Heart Institute Research Corporation
name: Pablo B. Nery, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04767477: Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors
Official title: Telerehabilitation and Face-to-face Rehabilitation on Tolerance to Exercise and Quality of Life of COVID-19 Survivors: a Study Protocol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Covid19
Exercise Tolerance
Quality of Life
Lung Function
Fatigue Intensity
Lead sponsor: Universidade Federal de Pernambuco
Sponsor class: OTHER
First posted: 2021-02-23
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: INTRODUCTION: As this is a new disease, the short- and long-term consequences for patients with COVID-19 are still unclear. The use of sedatives, as well as prolonged rest, can lead to musculoskeletal damage, including decreased muscle strength and physical function. Thus, rehabilitation after this disease is a key component in continuing patient care. OBJECTIVE: To verify the effects of face-to-face cardiac rehabilitation and telerehabilitation on tolerance to the maximum and submaximal exercise, lung function, fatigue intensity and quality of life of COVID-19 survivors. METHODS: This is a longitudinal, intervention study. Primary outcomes will be maximum and submaximal functional capacity, intensity and impact of fatigue, while secondary outcomes will be lung function and quality of life. EXPECTED RESULTS: This work will bring important information to the scientific community and health professionals, about the best forms of intervention and its repercussions on the surviving individuals of COVID-19.


Eligibility criteria: Inclusion Criteria:

* Adults of both genders;
* With a diagnosis of COVID-19 confirmed by a laboratory through RT-PCR means;
* Have to access to the internet and some device (smartphone, computer or notebook) that allows them to participate in the call centre.

Exclusion Criteria:

* Individuals with orthopaedic or neurological diseases;
* Individuals with difficulties in understanding and that present psychological changes that make it difficult or impossible to understand the information presented.

Primary outcomes:
measure: Maximum functional capacity
timeFrame: 12 weeks
measure: Submaximal functional capacity
timeFrame: 12 weeks
measure: Intensity and impact of fatigue
timeFrame: 12 weeks
Secondary outcomes:
measure: Spirometry
timeFrame: 12 weeks
measure: Quality of life assessment: Short Form-36 questionnaire
timeFrame: 12 weeks
Other outcomes:
measure: Perception of clinical change
timeFrame: 12 weeks
Locations:
city: Recife
country: Brazil
facility: Universidade Federal de Pernambuco
state: PE
Study officials:
References:
Clinical trial NCT00876577: VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis
Official title: VICTOR - Avelox® i.v. in Acute Exacerbations of Chronic Bronchitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Bronchitis
Disease Exacerbation
Keywords: Acute Exacerbations of Chronic Bronchitis
Avelox
Bronchitis
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2009-04-06
Enrollment: 1206
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult female and male patients with AECB, who are at least 18 years of age and are scheduled to be treated with Moxifloxacin injection, independent of the duration and severity of the underlying chronic bronchitis, can be documented after the therapy decision has been made.

Brief summary: This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of Moxifloxacin injection.The primary objective is to obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely prescribed. The secondary objective is to find out the possible correlation between the risk factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different treatment effectiveness according to Anthonisen classification. This study will also collect the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection in treating Acute Exacerbations of Chronic Bronchitis (AECB).


Eligibility criteria: Inclusion Criteria:

* Patients at least 18 years of age with a diagnosis of AECB treated with Moxifloxacin injection with/without sequential tablet treatment

Exclusion Criteria:

* Exclusion criteria must be read in conjunction with the local product information

Primary outcomes:
measure: clinical cure rate:clinical cure was defined as disappearance of acute signs and symptoms
timeFrame: up to 21 days
Secondary outcomes:
measure: Time to cure: time when symptoms are disappeared after Moxifloxacin treatment
timeFrame: up to 21 days
measure: Improvement time: time when patients feel improvemen
timeFrame: up to 21 days
measure: Time of patients recover from fever
timeFrame: up to 21 days
measure: Clinical efficacy rate of Moxifloxacin
timeFrame: up to 21 days
Other outcomes:
Locations:
city: Many Locations
country: China
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00143377: Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
Official title: A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Urinary Incontinence
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
Collaborators: name: Pfizer
First posted: 2005-09-02
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.


Eligibility criteria: Inclusion Criteria:

* 18 years or older patients suffering from OAB symptoms (urinary frequency of at least 8 micturitions per 24h, urinary urgency and at least 3 urge urinary incontinence episodes within 3 days), confirmed by a micturition bladder diary.

Exclusion Criteria:

* Other than urge incontinence
* History of prostate/uterine or other female organ cancer

Primary outcomes:
measure: Patient Perception of Bladder Condition at 12 weeks of treatment compared to placebo.
Secondary outcomes:
measure: Other safety and efficacy measures at 12 weeks of treatment.
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z; Disease Management Study Team. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Curr Med Res Opin. 2008 Dec;24(12):3513-21. doi: 10.1185/03007990802537122.
Clinical trial NCT00449345: Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Latent Tuberculosis Infection
Keywords: Latent tuberculosis infection
Health care workers
Tuberculin skin test
Mantoux skin test
Interferon gamma
Quantiferon
Cost effectiveness
Lead sponsor: Assuta Hospital Systems
Sponsor class: OTHER
Collaborators: name: Maccabi Healthcare Services, Israel
First posted: 2007-03-20
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable.

In recent years, more specific and sensitive tests based on interferon-gamma secretion to TB antigens have come to market, and most current evidence shows that many mantoux positive persons do not have LTBI. Quantiferon-GOLD is one of these assays.

In this prospective study, we will draw blood for the Quantiferon-GOLD assay in parallel to conventional testing, and perform a cost-effectiveness analysis of the cost of the investigation and treatment of LTBI in health-care workers.

We hypothesize that in spite of the cost of screening healthcare workers with Quantiferon-GOLD tests, the reduction in need for LTBI treatment and associated costs will render the test cost-effective.


Eligibility criteria: Inclusion Criteria:

* Health care worker undergoing screening for LTBI

Exclusion Criteria:

* Previous tuberculosis or treatment for LTBI
* Immunosuppressed due to drug treatment, HIV, organ transplant
* Recent TB contacts

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rehovot
country: Israel
facility: Community Tuberculosis service
Study officials:
affiliation: Maccabi Healthcare Services, Israel
name: David Shitrit, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06997445: Jacobson's Progressive Muscle Relaxation Technique With Aerobic Exercise on Cardiopulmonary Parameters and Quality of Life in Stage 1 Hypertensive Individuals
Official title: Additive Effects of Jacobson's Progressive Muscle Relaxation Technique With Aerobic Exercise on Cardiopulmonary Parameters and Quality of Life in Stage 1 Hypertensive Individuals
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Hypertension
Keywords: aerobic exercise
quality of life
hypertension
Muscle Relaxation
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2025-05-30
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is a randomized controlled trial. The purpose of study is to compare the additive effects of Jacobson's progressive muscle relaxation technique with aerobic exercise versus aerobic exercise on cardiopulmonary parameters including systolic and diastolic blood pressure, heart rate, respiratory rate, rate pressure product and quality of life in stage 1 hypertensive individuals.

Detailed description: The study will consist of referred stage 1 hypertensive patients by medical specialist/cardiologist.

Participants will be screened through PAR-Q and IPAQ Questionnaire. Cardiac monitor will be used for assessing the cardiopulmonary parameters. SF-36 Questionnaire will be used for assessing the quality of life. Informed written consent will be taken after which participants will be recruited into two groups.

Control group will be provided aerobic exercise while interventional group will be provided Jacobson's progressive muscle relaxation technique with aerobic exercise.

Outcome measures assessment will be done at pre-session, at 2 weeks and after 4 weeks post-intervention

Eligibility criteria: Inclusion Criteria:

* Adults: aged (18-45 years)
* Gender: both male and female
* Patients diagnosed with stage 1 hypertension (130-139 / 80-89 mmHg according to AHA/ACC 2017 guidelines
* Mild to moderate physical activity level on IPAQ Questionnaire
* Individuals who are able to understand and follow the instructions for exercise

Exclusion Criteria:

* Unstable angina, MI, heart failure, advanced CAD patients
* Severe neurological, musculoskeletal, or gynaecological conditions which limit participation in study
* Recent history of fracture
* Morbidly obese (BMI \> 40.0 kg / m2)

Primary outcomes:
measure: Systolic and diastolic blood pressure
timeFrame: 04 Weeks
measure: Heart rate
timeFrame: 04 Weeks
measure: Respiratory rate
timeFrame: 04 Weeks
measure: Rate pressure product
timeFrame: 04 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University College of Physical Therapy, Islamabad, 44000
Study officials:
References: